tipranavir

Known as: 3'-((1R)-1-((6R)-5,6-dihydro-4-hydroxy-2-oxo-6-phenethyl-6-propyl-2h-pyran-3-yl)propyl)-5-(trifluoromethyl)-2-pyridinesulfonanilide, tipranavir [Chemical/Ingredient] 
A non-peptidomimetic agent that inhibits both wild type and drug resistant forms of human immunodeficiency virus (HIV) protease.

Topic mentions per year

Topic mentions per year

1998-2018
020406019982018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
BACKGROUND The purpose of this study was to develop a tipranavir-weighted mutation score that provides guidance to treating… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2009
2009
Raltegravir (RAL) is a novel and potent human immunodeficiency virus type 1 integrase inhibitor that is predominantly metabolized… (More)
  • figure 1
  • table 1
  • figure 2
Is this relevant?
2008
2008
To identify mutations associated with the virological response (VR) to a tipranavir-ritonavir (TPV/r)-based regimen, 143 patients… (More)
Is this relevant?
2008
2008
BACKGROUND Tipranavir (TPV) and darunavir (DRV) are potent against protease inhibitor (PI)-resistant viruses. Efficacy of these… (More)
Is this relevant?
2007
2007
Drug resistance is a major problem affecting the clinical efficacy of antiretroviral agents, including protease inhibitors, in… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND Treatment options for HIV-1 infected individuals who have received extensive previous antiretroviral therapy are… (More)
Is this relevant?
2006
2006
Tipranavir is a novel, nonpeptidic protease inhibitor of human immunodeficiency virus type 1 (HIV-1) with activity against… (More)
Is this relevant?
2006
2006
BACKGROUND Tipranavir, a novel protease inhibitor, has demonstrated antiviral activity against protease inhibitor-resistant human… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2005
2005
Tipranavir is a novel, non-peptidic protease inhibitor, which possesses broad antiviral activity against multiple protease… (More)
Is this relevant?
2000
2000
OBJECTIVE Although the use of HIV-1 protease inhibitors (PI) has substantially benefited HIV-1-infected individuals, new PI are… (More)
Is this relevant?